CN102421742A - 3-戊基苯乙酸的盐及其药物用途 - Google Patents
3-戊基苯乙酸的盐及其药物用途 Download PDFInfo
- Publication number
- CN102421742A CN102421742A CN2010800201405A CN201080020140A CN102421742A CN 102421742 A CN102421742 A CN 102421742A CN 2010800201405 A CN2010800201405 A CN 2010800201405A CN 201080020140 A CN201080020140 A CN 201080020140A CN 102421742 A CN102421742 A CN 102421742A
- Authority
- CN
- China
- Prior art keywords
- salt
- illness
- experimenter
- kidney
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PEGQOIGYZLJMIB-UHFFFAOYSA-M CCCCCc1cc(CC([O-])=O)ccc1 Chemical compound CCCCCc1cc(CC([O-])=O)ccc1 PEGQOIGYZLJMIB-UHFFFAOYSA-M 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
- C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Abstract
Description
骨髓红细胞数(106) | 红细胞(109) | |
对照 | 20.3 | 7.1 |
环磷酰胺 | 8.1 | 5.7 |
化合物I | 11.5 | 7.0 |
Claims (28)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17521509P | 2009-05-04 | 2009-05-04 | |
US61/175,215 | 2009-05-04 | ||
PCT/CA2010/000691 WO2010127448A1 (en) | 2009-05-04 | 2010-05-03 | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102421742A true CN102421742A (zh) | 2012-04-18 |
CN102421742B CN102421742B (zh) | 2014-08-06 |
Family
ID=43049882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080020140.5A Active CN102421742B (zh) | 2009-05-04 | 2010-05-03 | 3-戊基苯乙酸的盐及其药物用途 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8637574B2 (zh) |
EP (1) | EP2427417B1 (zh) |
JP (1) | JP5844251B2 (zh) |
KR (1) | KR20120090011A (zh) |
CN (1) | CN102421742B (zh) |
AU (1) | AU2010244938A1 (zh) |
BR (1) | BRPI1015118A2 (zh) |
CA (1) | CA2761061A1 (zh) |
DK (1) | DK2427417T3 (zh) |
ES (1) | ES2441800T3 (zh) |
HK (1) | HK1169379A1 (zh) |
MX (1) | MX2011011756A (zh) |
PL (1) | PL2427417T3 (zh) |
PT (1) | PT2427417E (zh) |
TW (1) | TWI458481B (zh) |
WO (1) | WO2010127448A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105997967A (zh) * | 2010-10-27 | 2016-10-12 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
CN107106526A (zh) * | 2014-11-12 | 2017-08-29 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
CN110105200A (zh) * | 2013-03-15 | 2019-08-09 | 普罗米蒂克医药Smt有限公司 | 用于治疗纤维化的经取代的芳族化合物及相关方法 |
WO2021036495A1 (zh) * | 2019-08-29 | 2021-03-04 | 广东药科大学 | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2427416T3 (en) | 2009-05-04 | 2016-06-13 | Prometic Pharma Smt Ltd | Substituted aromatic compounds, and pharmaceutical uses thereof |
US20130225683A1 (en) * | 2010-10-27 | 2013-08-29 | Prometic Biosciences Inc. | Compounds and Pharmaceutical Compositions for Uses in Diabetes |
TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
CN106999456B (zh) * | 2014-10-10 | 2020-07-10 | 里米诺生物科学有限公司 | 用于预防和治疗骨质疏松症的被取代的芳族化合物和药物组合物 |
WO2020113340A1 (en) * | 2018-12-05 | 2020-06-11 | Liminal Biosciences Limited | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alström syndrome |
EP4051659A1 (en) * | 2019-10-31 | 2022-09-07 | Teva Pharmaceuticals International GmbH | Solid state forms of fezagepras and process for preparation thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3228831A (en) * | 1961-02-02 | 1966-01-11 | Boots Pure Drug Co Ltd | Compositions and method for treating symptoms of inflammation, pain and fever |
US3894080A (en) * | 1970-05-05 | 1975-07-08 | Rorer Inc William H | Phenylacetic acids |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3385887A (en) * | 1961-02-02 | 1968-05-28 | Boots Pure Drug Co Ltd | 4-isobutylphenylacetic acid |
WO2005010202A2 (en) * | 2003-07-16 | 2005-02-03 | Ligand Pharmacueticals Incorporated | PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS |
DK2427416T3 (en) * | 2009-05-04 | 2016-06-13 | Prometic Pharma Smt Ltd | Substituted aromatic compounds, and pharmaceutical uses thereof |
-
2010
- 2010-05-03 US US13/318,252 patent/US8637574B2/en active Active
- 2010-05-03 DK DK10771941.1T patent/DK2427417T3/da active
- 2010-05-03 AU AU2010244938A patent/AU2010244938A1/en not_active Abandoned
- 2010-05-03 JP JP2012508864A patent/JP5844251B2/ja not_active Expired - Fee Related
- 2010-05-03 BR BRPI1015118A patent/BRPI1015118A2/pt not_active Application Discontinuation
- 2010-05-03 PL PL10771941T patent/PL2427417T3/pl unknown
- 2010-05-03 WO PCT/CA2010/000691 patent/WO2010127448A1/en active Application Filing
- 2010-05-03 EP EP10771941.1A patent/EP2427417B1/en active Active
- 2010-05-03 MX MX2011011756A patent/MX2011011756A/es active IP Right Grant
- 2010-05-03 CA CA2761061A patent/CA2761061A1/en not_active Abandoned
- 2010-05-03 KR KR1020117028776A patent/KR20120090011A/ko not_active Application Discontinuation
- 2010-05-03 TW TW099114043A patent/TWI458481B/zh active
- 2010-05-03 CN CN201080020140.5A patent/CN102421742B/zh active Active
- 2010-05-03 ES ES10771941.1T patent/ES2441800T3/es active Active
- 2010-05-03 PT PT107719411T patent/PT2427417E/pt unknown
-
2012
- 2012-10-15 HK HK12110169.0A patent/HK1169379A1/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3228831A (en) * | 1961-02-02 | 1966-01-11 | Boots Pure Drug Co Ltd | Compositions and method for treating symptoms of inflammation, pain and fever |
US3894080A (en) * | 1970-05-05 | 1975-07-08 | Rorer Inc William H | Phenylacetic acids |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105997967A (zh) * | 2010-10-27 | 2016-10-12 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
CN105997967B (zh) * | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
CN110105200A (zh) * | 2013-03-15 | 2019-08-09 | 普罗米蒂克医药Smt有限公司 | 用于治疗纤维化的经取代的芳族化合物及相关方法 |
CN110105200B (zh) * | 2013-03-15 | 2022-04-12 | 里米诺生物科学有限公司 | 用于治疗纤维化的经取代的芳族化合物及相关方法 |
CN107106526A (zh) * | 2014-11-12 | 2017-08-29 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
CN107106526B (zh) * | 2014-11-12 | 2021-05-28 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
WO2021036495A1 (zh) * | 2019-08-29 | 2021-03-04 | 广东药科大学 | 新型苯乙酸衍生物、其制备方法及其作为药物的用途 |
Also Published As
Publication number | Publication date |
---|---|
HK1169379A1 (zh) | 2013-01-25 |
MX2011011756A (es) | 2012-01-25 |
DK2427417T3 (da) | 2014-01-20 |
KR20120090011A (ko) | 2012-08-16 |
JP2012526053A (ja) | 2012-10-25 |
TWI458481B (zh) | 2014-11-01 |
TW201043226A (en) | 2010-12-16 |
BRPI1015118A2 (pt) | 2016-04-12 |
WO2010127448A1 (en) | 2010-11-11 |
CA2761061A1 (en) | 2010-11-11 |
US8637574B2 (en) | 2014-01-28 |
ES2441800T3 (es) | 2014-02-06 |
CN102421742B (zh) | 2014-08-06 |
EP2427417A1 (en) | 2012-03-14 |
JP5844251B2 (ja) | 2016-01-13 |
US20120095102A1 (en) | 2012-04-19 |
EP2427417B1 (en) | 2013-10-09 |
PT2427417E (pt) | 2014-01-13 |
EP2427417A4 (en) | 2012-09-26 |
PL2427417T3 (pl) | 2014-03-31 |
AU2010244938A1 (en) | 2011-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102421742B (zh) | 3-戊基苯乙酸的盐及其药物用途 | |
CN102438975A (zh) | 取代的芳香化合物及其药物用途 | |
CN100430048C (zh) | 治疗下泌尿道症状的α-2-δ配体 | |
CN108601791A (zh) | 结晶方法和生物利用度 | |
CN105392483B (zh) | 用于抑制磷酸盐转运的nhe3结合化合物和方法 | |
UA126959C2 (uk) | Фармацевтична композиція, що містить інгібітор тирозинкінази брутона | |
CN104837503A (zh) | 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法 | |
CN101243096A (zh) | 抗病毒化合物 | |
CN104039775A (zh) | Atp-结合盒转运蛋白的调节剂 | |
CN104902930A (zh) | 在治疗与液体潴留或盐分过载相关的疾病和胃肠道疾病中用于抑制nhe-介导的反向转运的化合物和方法 | |
MX2008011140A (es) | Composicion farmaceutica conteniendo ghrp-6 capaz de prevenir y eliminar las fibrosis y otras formas de deposito patologico en los tejidos. | |
WO2011156003A2 (en) | Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same | |
JP2016210814A (ja) | カルボン酸フェニルケトン化合物およびその薬学的使用 | |
CN105101987A (zh) | 新型的稳定十五肽盐,其制备方法,其在制备药物制剂中的用途以及其治疗用途 | |
EP1720552A2 (en) | Methods for treating inflammatory and autoimmune diseases | |
WO2021093697A1 (zh) | 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法 | |
CN108658879A (zh) | 一种urat1抑制剂及其制备方法和用途 | |
WO2022111493A1 (zh) | Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途 | |
TW201225953A (en) | Pharmaceutical composition and health food for liver fibrosis, cirrhosis and hepatitis | |
CN113999284A (zh) | 用于抗埃博拉病毒的环状多肽或其药用盐 | |
RU2589258C1 (ru) | Средство пептидной структуры, ингибирующее дипептидилпептидазу-4, и фармацевтическая композиция на его основе | |
CN107619428A (zh) | 鸟氨酸与门冬氨酸二肽化合物的酰化衍生物及其应用 | |
CN104434850A (zh) | 一种含有阿德福韦酯的口服固体药物组合物 | |
RU2295335C2 (ru) | Лекарственные препараты, обладающие иммуномодулирующим, противовоспалительным и противоопухолевым свойствами, и способ их получения | |
JP2010513219A (ja) | 腎臓の疾患、糖尿病性腎症及び脂質代謝異常の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1169379 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1169379 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160725 Address after: cambridge Patentee after: The general Midike Pharmaceutical Co. Ltd. SMT Address before: Quebec Patentee before: Prometic Biosciences Inc. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof Effective date of registration: 20181016 Granted publication date: 20140806 Pledgee: Structured Alfa limited partnership Pledgor: The general Midike Pharmaceutical Co. Ltd. SMT Registration number: 2018990000969 |